Chicharro-Manso P, Rodríguez-Jiménez P, Pérez-Plaza A, Llamas-Velasco M, Sánchez-Pérez J

Language: Spanish
References: 6
Page: 123-126
PDF size: 314.65 Kb.

ABSTRACT

Background: Sorafenib is a multitargeted kinase inhibitor used in the treatment of several cancers, including hepato-cellular carcinoma, renal cell carcinoma and thyroid carcinoma. This treatment has been associated with several cutaneous adverse effects. Objectives: We conducted this study to evaluate in our environment the frequency and types of these adverse effects. Material and methods: We performed a retrospective study of 74 patients treated with sorafenib in our hospital, collecting general clinical data and the cutaneous lesions developed. Results: Within the 74 patients treated with sorafenib, 24 (32%) developed cutaneous adverse effects. The most frequent adverse effect was hand-food skin reaction (HFSR). Other adverse events were maculopapular eruption, xerosis, alopecia and follicular hyperkeratosis. All events appeared in the first months of treatment and, most frequently, this could be continued. Conclusion: Sorafenib is associated with a high rate of cutaneous adverse effects, being HFSR the most frequent.

REFERENCES

1. Ara M, Pastushenko E. Fármacos antiangiogénicos y piel: efectos cutáneos adversos de sorafenib, sunitinib y bevacizumab. Actas Dermosifilogr. 2014; 105: 900-912.

2. Zhang L, Zhou Q, Ma L, Wu Z, Wang Y. Meta-analysis of dermatological toxicities associated with sorafenib. Clin Exp Dermatol. 2011; 36 (4): 344-350.

3. Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol. 2008; 144 (7): 886-892.

4. Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Chol JH et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009; 161 (5): 1045-1051.

5. Robert C, Mateus C, Spatz A, Wechsler J, Escudier B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol. 2009; 60 (2): 299-305.

6. Kong HH, Turner ML. The array of cutaneous adverse effects associated with sorafenib. J Am Acad Dermatol. 2009; 61: 360-361.